Comprehensive Stock Comparison
Compare Cellebrite DI Ltd. (CLBT) vs Oracle Corporation (ORCL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CLBT | 18.6% revenue growth vs ORCL's 8.4% |
| Value | CLBT | PEG 0.62 vs 2.78 |
| Quality / Margins | ORCL | 25.3% net margin vs CLBT's 16.5% |
| Stability / Safety | CLBT | Beta 0.83 vs ORCL's 1.40, lower leverage |
| Dividends | ORCL | 1.1% yield; 18-year raise streak; CLBT pays no meaningful dividend |
| Momentum (1Y) | ORCL | -11.2% vs CLBT's -28.1% |
| Efficiency (ROA) | CLBT | 8.3% ROA vs ORCL's 7.5%, ROIC 18.5% vs 12.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Valuation efficiency (growth/$)
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Cellebrite provides digital intelligence solutions for legally sanctioned investigations by law enforcement and government agencies. It generates revenue primarily from software licenses and maintenance fees for its forensic data extraction and analysis platforms — including its Universal Forensic Extraction Device and DI platform — which help investigators access and analyze digital evidence from locked, encrypted, or deleted sources. The company's key advantage is its deep technical expertise in overcoming device security barriers and its established relationships with government agencies worldwide, creating high switching costs in a specialized, regulated market.
Oracle is a global enterprise software and cloud computing company that provides database management systems, enterprise applications, and cloud infrastructure services. It generates revenue primarily through cloud services and license support (~70% of total revenue) and cloud license and on-premise license sales (~20%), with hardware and services making up the remainder. The company's key moat is its entrenched position in enterprise database software—particularly with its flagship Oracle Database—which creates significant switching costs and lock-in for large corporate customers.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CLBT leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). ORCL leads in 1 (Analyst Outlook). 3 tied.
Financial Metrics (TTM)
ORCL is the larger business by revenue, generating $61.0B annually — 128.3x CLBT's $476M. ORCL is the more profitable business, keeping 25.3% of every revenue dollar as net income compared to CLBT's 16.5%. On growth, CLBT holds the edge at +18.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CLBTCellebrite DI Ltd. | ORCLOracle Corporation |
|---|---|---|
| RevenueTrailing 12 months | $476M | $61.0B |
| EBITDAEarnings before interest/tax | $78M | $22.6B |
| Net IncomeAfter-tax profit | $78M | $15.4B |
| Free Cash FlowCash after capex | $160M | -$13.2B |
| Gross MarginGross profit ÷ Revenue | +84.2% | +70.7% |
| Operating MarginEBIT ÷ Revenue | +14.0% | +30.3% |
| Net MarginNet income ÷ Revenue | +16.5% | +25.3% |
| FCF MarginFCF ÷ Revenue | +33.7% | -21.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.1% | +14.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.7% | +90.9% |
Valuation Metrics
At 33.5x trailing earnings, ORCL trades at a 22% valuation discount to CLBT's 43.0x P/E. Adjusting for growth (PEG ratio), CLBT offers better value at 0.73x vs ORCL's 4.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | CLBTCellebrite DI Ltd. | ORCLOracle Corporation |
|---|---|---|
| Market CapShares × price | $3.3B | $408.1B |
| Enterprise ValueMkt cap + debt − cash | $3.2B | $501.5B |
| Trailing P/EPrice ÷ TTM EPS | 43.03x | 33.50x |
| Forward P/EPrice ÷ next-FY EPS est. | 36.25x | 19.71x |
| PEG RatioP/E ÷ EPS growth rate | 0.73x | 4.72x |
| EV / EBITDAEnterprise value multiple | 40.33x | 21.02x |
| Price / SalesMarket cap ÷ Revenue | 6.86x | 7.11x |
| Price / BookPrice ÷ Book value/share | 6.88x | 19.87x |
| Price / FCFMarket cap ÷ FCF | 20.34x | — |
Profitability & Efficiency
ORCL delivers a 50.6% return on equity — every $100 of shareholder capital generates $51 in annual profit, vs $16 for CLBT. CLBT carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to ORCL's 4.96x. On the Piotroski fundamental quality scale (0–9), ORCL scores 6/9 vs CLBT's 4/9, reflecting solid financial health.
| Metric | CLBTCellebrite DI Ltd. | ORCLOracle Corporation |
|---|---|---|
| ROE (TTM)Return on equity | +16.2% | +50.6% |
| ROA (TTM)Return on assets | +8.3% | +7.5% |
| ROICReturn on invested capital | +18.5% | +12.8% |
| ROCEReturn on capital employed | +13.8% | +14.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.05x | 4.96x |
| Net DebtTotal debt minus cash | -$102M | $93.3B |
| Cash & Equiv.Liquid assets | $124M | $10.8B |
| Total DebtShort + long-term debt | $23M | $104.1B |
| Interest CoverageEBIT ÷ Interest expense | — | 3.24x |
Total Returns (with DRIP)
A $10,000 investment in ORCL five years ago would be worth $23,146 today (with dividends reinvested), compared to $12,549 for CLBT. Over the past 12 months, ORCL leads with a -11.2% total return vs CLBT's -28.1%. The 3-year compound annual growth rate (CAGR) favors CLBT at 29.4% vs ORCL's 19.9% — a key indicator of consistent wealth creation.
| Metric | CLBTCellebrite DI Ltd. | ORCLOracle Corporation |
|---|---|---|
| YTD ReturnYear-to-date | -25.2% | -25.5% |
| 1-Year ReturnPast 12 months | -28.1% | -11.2% |
| 3-Year ReturnCumulative with dividends | +116.9% | +72.3% |
| 5-Year ReturnCumulative with dividends | +25.5% | +131.5% |
| 10-Year ReturnCumulative with dividends | +38.1% | +327.4% |
| CAGR (3Y)Annualised 3-year return | +29.4% | +19.9% |
Risk & Volatility
CLBT is the less volatile stock with a 0.83 beta — it tends to amplify market swings less than ORCL's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLBT currently trades 64.0% from its 52-week high vs ORCL's 42.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CLBTCellebrite DI Ltd. | ORCLOracle Corporation |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.83x | 1.40x |
| 52-Week HighHighest price in past year | $20.86 | $345.72 |
| 52-Week LowLowest price in past year | $11.76 | $118.86 |
| % of 52W HighCurrent price vs 52-week peak | +64.0% | +42.1% |
| RSI (14)Momentum oscillator 0–100 | 43.9 | 41.2 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 20.9M |
Analyst Outlook
Wall Street rates CLBT as "Buy" and ORCL as "Buy". Consensus price targets imply 103.5% upside for ORCL (target: $296) vs 54.9% for CLBT (target: $21). ORCL is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.
| Metric | CLBTCellebrite DI Ltd. | ORCLOracle Corporation |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $20.67 | $295.85 |
| # AnalystsCovering analysts | 8 | 86 |
| Dividend YieldAnnual dividend ÷ price | — | +1.1% |
| Dividend StreakConsecutive years of raises | 1 | 18 |
| Dividend / ShareAnnual DPS | — | $1.65 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 20 | Feb 26 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | 100 | 154.24 | +54.2% |
| Oracle Corporation (ORCL) | 100 | 272.49 | +172.5% |
Oracle Corporation (ORCL) returned +131% over 5 years vs Cellebrite DI Ltd. (CLBT)'s +25%. A $10,000 investment in ORCL 5 years ago would be worth $23,146 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | $172M | $476M | +176.8% |
| Oracle Corporation (ORCL) | $37.0B | $57.4B | +54.9% |
Oracle Corporation's revenue grew from $37.0B (2016) to $57.4B (2025) — a 5.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | -1.1% | 16.5% | +1608.5% |
| Oracle Corporation (ORCL) | 24.0% | 21.7% | -9.8% |
Oracle Corporation's net margin went from 24% (2016) to 22% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | 340.8 | 58.2 | -82.9% |
| Oracle Corporation (ORCL) | 21.4 | 44.9 | +109.8% |
Cellebrite DI Ltd. has traded in a 7x–341x P/E range over 4 years; current trailing P/E is ~43x. Oracle Corporation has traded in a 18x–53x P/E range over 9 years; current trailing P/E is ~34x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | -0.01 | 0.31 | +3200.0% |
| Oracle Corporation (ORCL) | 2.07 | 4.34 | +109.7% |
Oracle Corporation's EPS grew from $2.07 (2016) to $4.34 (2025) — a 9% CAGR.
Chart 6Free Cash Flow — 5 Years
Cellebrite DI Ltd. generated $160M FCF in 2025 (+474% vs 2021). Oracle Corporation generated $-394M FCF in 2025 (-103% vs 2021).
CLBT vs ORCL: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CLBT or ORCL a better buy right now?
Oracle Corporation (ORCL) offers the better valuation at 33.5x trailing P/E (19.7x forward), making it the more compelling value choice. Analysts rate Cellebrite DI Ltd. (CLBT) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CLBT or ORCL?
On trailing P/E, Oracle Corporation (ORCL) is the cheapest at 33.5x versus Cellebrite DI Ltd. at 43.0x. On forward P/E, Oracle Corporation is actually cheaper at 19.7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Cellebrite DI Ltd. wins at 0.62x versus Oracle Corporation's 2.78x — a PEG below 1.0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CLBT or ORCL?
Over the past 5 years, Oracle Corporation (ORCL) delivered a total return of +131.5%, compared to +25.5% for Cellebrite DI Ltd. (CLBT). A $10,000 investment in ORCL five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ORCL returned +327.4% versus CLBT's +38.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CLBT or ORCL?
By beta (market sensitivity over 5 years), Cellebrite DI Ltd. (CLBT) is the lower-risk stock at 0.83β versus Oracle Corporation's 1.40β — meaning ORCL is approximately 70% more volatile than CLBT relative to the S&P 500. On balance sheet safety, Cellebrite DI Ltd. (CLBT) carries a lower debt/equity ratio of 5% versus 5% for Oracle Corporation — giving it more financial flexibility in a downturn.
05Which has better profit margins — CLBT or ORCL?
Oracle Corporation (ORCL) is the more profitable company, earning 21.7% net margin versus 16.5% for Cellebrite DI Ltd. — meaning it keeps 21.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ORCL leads at 30.8% versus 14.0% for CLBT. At the gross margin level — before operating expenses — CLBT leads at 84.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CLBT or ORCL more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Cellebrite DI Ltd. (CLBT) is the more undervalued stock at a PEG of 0.62x versus Oracle Corporation's 2.78x. A PEG below 1.0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Oracle Corporation (ORCL) trades at 19.7x forward P/E versus 36.3x for Cellebrite DI Ltd. — 16.5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ORCL: 103.5% to $295.85.
07Which pays a better dividend — CLBT or ORCL?
In this comparison, ORCL (1.1% yield) pays a dividend. CLBT does not pay a meaningful dividend and should not be held primarily for income.
08Is CLBT or ORCL better for a retirement portfolio?
For long-horizon retirement investors, Oracle Corporation (ORCL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.1% yield, +327.4% 10Y return). Both have compounded well over 10 years (ORCL: +327.4%, CLBT: +38.1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CLBT and ORCL?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. ORCL pays a dividend while CLBT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.